137 related articles for article (PubMed ID: 31372837)
1. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials.
Niederman MS; Lee PC; Barriere SL; Barnes CN; Castaneda-Ruiz B
Infect Dis Ther; 2019 Sep; 8(3):445-452. PubMed ID: 31372837
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia.
Rubinstein E; Stryjewski ME; Barriere SL
Infect Drug Resist; 2014; 7():129-35. PubMed ID: 24876786
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.
Smart JI; Corey GR; Stryjewski ME; Wang W; Barriere SL
Infect Dis Ther; 2016 Dec; 5(4):535-544. PubMed ID: 27718118
[TBL] [Abstract][Full Text] [Related]
4. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
[TBL] [Abstract][Full Text] [Related]
5. Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials.
Nogid B; Lacy MK; Jacobs M; Bruss J; Dwyer J
Pharmacotherapy; 2018 Oct; 38(10):990-998. PubMed ID: 30003567
[TBL] [Abstract][Full Text] [Related]
6. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
7. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.
Torres A; Rubinstein E; Corey GR; Stryjewski ME; Barriere SL
J Antimicrob Chemother; 2014 Apr; 69(4):1119-26. PubMed ID: 24398339
[TBL] [Abstract][Full Text] [Related]
9. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
[TBL] [Abstract][Full Text] [Related]
10. Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies.
Wilson SE; Graham DR; Wang W; Bruss JB; Castaneda-Ruiz B
Infect Dis Ther; 2017 Sep; 6(3):413-422. PubMed ID: 28695347
[TBL] [Abstract][Full Text] [Related]
11. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia.
Haque NZ; Zuniga LC; Peyrani P; Reyes K; Lamerato L; Moore CL; Patel S; Allen M; Peterson E; Wiemken T; Cano E; Mangino JE; Kett DH; Ramirez JA; Zervos MJ;
Chest; 2010 Dec; 138(6):1356-62. PubMed ID: 20558550
[TBL] [Abstract][Full Text] [Related]
12. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.
Awad SS; Rodriguez AH; Chuang YC; Marjanek Z; Pareigis AJ; Reis G; Scheeren TW; Sánchez AS; Zhou X; Saulay M; Engelhardt M
Clin Infect Dis; 2014 Jul; 59(1):51-61. PubMed ID: 24723282
[TBL] [Abstract][Full Text] [Related]
13. The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia.
Barriere SL
Future Microbiol; 2014; 9(3):281-9. PubMed ID: 24450506
[TBL] [Abstract][Full Text] [Related]
14. Telavancin: a review of its use in patients with nosocomial pneumonia.
Scott LJ
Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
[TBL] [Abstract][Full Text] [Related]
15. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
Polyzos KA; Mavros MN; Vardakas KZ; Makris MC; Rafailidis PI; Falagas ME
PLoS One; 2012; 7(8):e41870. PubMed ID: 22916113
[TBL] [Abstract][Full Text] [Related]
17. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.
Das B; Sarkar C; Das D; Gupta A; Kalra A; Sahni S
Ther Adv Infect Dis; 2017 Mar; 4(2):49-73. PubMed ID: 28634536
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.
Stryjewski ME; Barriere SL; O'Riordan W; Dunbar LM; Hopkins A; Genter FC; Corey GR
J Antimicrob Chemother; 2012 Jun; 67(6):1496-502. PubMed ID: 22416054
[TBL] [Abstract][Full Text] [Related]
19. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
[TBL] [Abstract][Full Text] [Related]
20. Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.
Liapikou A; Dimakou K; Toumbis M
Ther Adv Respir Dis; 2016 Aug; 10(4):368-78. PubMed ID: 27340253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]